Literature DB >> 23321539

Attenuation of MPTP/MPP(+) toxicity in vivo and in vitro by an 18-mer peptide derived from prosaposin.

H L Gao1, C Li, H Nabeka, T Shimokawa, S Saito, Z Y Wang, Y M Cao, S Matsuda.   

Abstract

Parkinson's disease (PD) is a chronic progressive neurological disorder with an increasing incidence in the aging population. Neuroprotective and/or neuroregenerative strategies remain critical in the treatment of this increasingly prevalent disease. Prosaposin is a neurotrophic factor whose neurotrophic activity is attributed to a stretch of 12 amino acids located at the N-terminal region of saposin C. The present study was performed to investigate the protective effect and mechanism of action of a prosaposin-derived 18-mer peptide (PS18: LSELIINNATEELLIKGL) in Parkinson's disease models. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 1-methyl-4-phenylpyridinium ion (MPP(+))-induced dopaminergic neurotoxicity in C57BL/6J mice or SH-SY5Y cells and explored the protective effect and mechanisms of action of PS18 on dopaminergic neurons. Treatment with 2.0mg/kg PS18 significantly improved behavioral deficits, enhanced the survival of tyrosine hydroxylase-positive neurons, and decreased the activity of astrocytes in the substantia nigra and striatum in MPTP-induced PD model mice. In vitro, a Cell Counting Kit-8 assay and Hoechst 33258 staining revealed that co-treatment with 300ng/mL PS18 and 5mM MPP(+) protected against MPP(+)-induced nuclear morphological changes and attenuated cell death induced by MPP(+). We also found that PS18-FAM entered the cells, and the retention time of PS18-FAM in the cytoplasm of MPP(+)-treated cells was shorter than that of untreated cells. In addition, PS18 showed protection from MPP(+)/MPTP-induced apoptosis in the SH-SY5Y cells and dopaminergic neurons in the PD model mice via suppression of the c-Jun N-terminal kinase/c-Jun pathway; upregulation of Bcl-2; downregulation of BAX, attenuating mitochondrial damage; and inhibition of caspase-3. These findings suggest that PS18 may provide a valuable therapeutic strategy for the treatment of progressive neurodegenerative diseases such as PD.
Copyright © 2013 IBRO. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321539     DOI: 10.1016/j.neuroscience.2013.01.007

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  18 in total

1.  Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.

Authors:  Zheng Liu; Wei Cai; Ming Lang; Ruizuo Yan; Zhenshen Li; Gaoxiao Zhang; Pei Yu; Yuqiang Wang; Yewei Sun; Zaijun Zhang
Journal:  J Mol Neurosci       Date:  2017-01-31       Impact factor: 3.444

2.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

Review 3.  The protective role of prosaposin and its receptors in the nervous system.

Authors:  Rebecca C Meyer; Michelle M Giddens; Brilee M Coleman; Randy A Hall
Journal:  Brain Res       Date:  2014-08-15       Impact factor: 3.252

Review 4.  Prosaposin, a neurotrophic factor, protects neurons against kainic acid-induced neurotoxicity.

Authors:  Hiroaki Nabeka
Journal:  Anat Sci Int       Date:  2021-02-03       Impact factor: 1.741

5.  Prosaposin Reduces α-Synuclein in Cells and Saposin C Dislodges it from Glucosylceramide-enriched Lipid Membranes.

Authors:  Rika Kojima; Mark Zurbruegg; Tianyi Li; Wojciech Paslawski; Xiaoqun Zhang; Per Svenningsson
Journal:  J Mol Neurosci       Date:  2022-09-24       Impact factor: 2.866

6.  PARK14 (D331Y) PLA2G6 Causes Early-Onset Degeneration of Substantia Nigra Dopaminergic Neurons by Inducing Mitochondrial Dysfunction, ER Stress, Mitophagy Impairment and Transcriptional Dysregulation in a Knockin Mouse Model.

Authors:  Ching-Chi Chiu; Chin-Song Lu; Yi-Hsin Weng; Ying-Ling Chen; Ying-Zu Huang; Rou-Shayn Chen; Yi-Chuan Cheng; Yin-Cheng Huang; Yu-Chuan Liu; Szu-Chia Lai; Kun-Jun Lin; Yan-Wei Lin; Yu-Jie Chen; Chao-Lang Chen; Tu-Hsueh Yeh; Hung-Li Wang
Journal:  Mol Neurobiol       Date:  2018-08-08       Impact factor: 5.590

7.  GPR37 protein trafficking to the plasma membrane regulated by prosaposin and GM1 gangliosides promotes cell viability.

Authors:  Ebba Gregorsson Lundius; Vladana Vukojevic; Ellen Hertz; Nikolas Stroth; Andreas Cederlund; Masao Hiraiwa; Lars Terenius; Per Svenningsson
Journal:  J Biol Chem       Date:  2013-12-26       Impact factor: 5.157

8.  Prosaposin overexpression following kainic acid-induced neurotoxicity.

Authors:  Hiroaki Nabeka; Keigo Uematsu; Hiroko Takechi; Tetsuya Shimokawa; Kimiko Yamamiya; Cheng Li; Takuya Doihara; Shouichiro Saito; Naoto Kobayashi; Seiji Matsuda
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

9.  Temporal changes in prosaposin expression in the rat dentate gyrus after birth.

Authors:  Midori Morishita; Hiroaki Nabeka; Tetsuya Shimokawa; Kyojy Miyawaki; Takuya Doihara; Shouichiro Saito; Naoto Kobayashi; Seiji Matsuda
Journal:  PLoS One       Date:  2014-05-28       Impact factor: 3.240

10.  Decrease in prosaposin in the Dystrophic mdx mouse brain.

Authors:  Hui-Ling Gao; Cheng Li; Hiroaki Nabeka; Tetsuya Shimokawa; Naoto Kobayashi; Shouichiro Saito; Zhan-You Wang; Ya-Ming Cao; Seiji Matsuda
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.